-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx Pharma unit GeNeuro wins European patent for ALS antibody candidate GNK-301

PUBT·09/14/2026 11:04:52
Listen to the news
NRx Pharma unit GeNeuro wins European patent for ALS antibody candidate GNK-301
  • NRx Pharmaceuticals’ GeNeuro unit won a European patent covering GNK-301, a monoclonal antibody targeting HERV-K envelope protein in ALS.
  • K Env was detected in spinal fluid of more than 75% of ALS patients; GNK-301 blocked neurotoxic effects in preclinical models.
  • GeNeuro started cGMP manufacturing; Phase 1 ALS trials are planned for the second half of 2027 in the US and Europe.
  • The invention is co-owned with the US Department of Health and Human Services; related US patents have already been issued.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140700PRIMZONEFULLFEED9826096) on September 14, 2026, and is solely responsible for the information contained therein.